Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CD24-Fc; CD24-Fc-IgG; CD24Fc-fusion protein; Recombinant CD24 IgG1 Fc fusion protein; Recombinant human CD24FcIg

Latest Information Update: 28 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoImmune
  • Developer National Institute of Neurological Disorders and Stroke; OncoImmune
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections; Graft-versus-host disease
  • No development reported Autoimmune disorders

Most Recent Events

  • 24 Sep 2020 Interim efficacy data from a phase III SAC-COVID trial in COVID-2019 infections released by OncoImmune
  • 17 Sep 2020 University of California, Davis in collaboration with OncoImmune and National Cancer Institute plans a phase I/II trial (TIRAEC) for Solid tumors (Late-stage disease, Second-line therapy or greater) in USA in October 2020 (NCT04552704)
  • 15 Sep 2020 Phase-III clinical trials in Graft-versus-host disease (Prevention) in USA (IV) (NCT04095858)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top